Antibody-targeted nanoparticles for cancer therapy

Immunotherapy

Volumn 3, Issue 3, 2011, Pages 381-394

  Fay, Francois ^a   Scott, Christopher J ^a  

^a QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

Author keywords

anticancer; drug delivery; immunotargeting; liposome; nanoparticle; quantum dot; receptor mediated endocytosis

Indexed keywords

ANTIBODY CONJUGATE; DENDRIMER; GOLD NANOPARTICLE; LIPOSOME; NANOPARTICLE; NIOSOME; SINGLE WALLED NANOTUBE;

CANCER IMMUNOTHERAPY; DRUG CONJUGATION; DRUG DELIVERY SYSTEM; DRUG RELEASE; DRUG TARGETING; HUMAN; MICELLE; NEOPLASM; NONHUMAN; PRIORITY JOURNAL; REVIEW;

ANIMALS; ANTIBODIES, MONOCLONAL; DENDRIMERS; DRUG DELIVERY SYSTEMS; HUMANS; IMMUNOTHERAPY; LIPOSOMES; MICE; MICELLES; NANOMEDICINE; NANOSTRUCTURES; NEOPLASMS; RECEPTORS, CELL SURFACE;

EID: 79952649516     PISSN: 1750743X     EISSN: None     Source Type: Journal    
DOI: 10.2217/imt.11.5     Document Type: Review

References (185)

1. Cowens JW, Creaven PJ, Greco WR et al.: Initial clinical (Phase I) trial of TLC D-99 (doxorubicin encapsulated in liposomes). Cancer Res. 53, 2796-2802 (1993). (Pubitemid 23180518)
2. Chu D, Lacouture ME, Weiner E, Wu S: Risk of hand-foot skin reaction with the multitargeted kinase inhibitor sunitinib in patients with renal cell and non-renal cell carcinoma: a meta-analysis. Clin. Genitourin. Cancer 7, 11-19 (2009).
3. Darby SC, Cutter DJ, Boerma M et al.: Radiation-related heart disease: current knowledge and future prospects. Int. J. Radiat. Oncol. Biol. Phys. 76, 656-665 (2010).
4. Sparreboom A, de Jonge MJ, Verweij J: The use of oral cytotoxic and cytostatic drugs in cancer treatment. Eur. J. Cancer 38, 18-22 (2002). (Pubitemid 34031821)
5. van der Vijgh WJ: Clinical pharmacokinetics of carboplatin. Clin. Pharmacokinet. 21, 242-261 (1991).
6. Desilet N, Campbell TN, Choy FY: p53-based anti-cancer therapies: an empty promise? Curr. Issues Mol. Biol. 12, 143-146 (2010).
7. Vanniasinghe AS, Bender V, Manolios N: The potential of liposomal drug delivery for the treatment of inflammatory arthritis. Semin. Arthritis Rheum. 39, 182-196 (2009).
8. El-Sayed IH, Huang X, El-Sayed MA: Surface plasmon resonance scattering and absorption of anti-EGFR antibody conjugated gold nanoparticles in cancer diagnostics: applications in oral cancer. Nano Lett. 5, 829-834 (2005). (Pubitemid 40749040)
9. Huang X, Jain PK, El-Sayed IH, El-Sayed MA: Determination of the minimum temperature required for selective photothermal destruction of cancer cells with the use of immunotargeted gold nanoparticles. Photochem. Photobiol. 82, 412-417 (2006).
10. Conti PS, White C, Pieslor P, Molina A, Aussie J, Foster P: The role of imaging with 111In-ibritumomabtiuxetan in the ibritumomabtiuxetan (Zevalin) regimen: results from a Zevalin Imaging Registry. J. Nucl. Med. 46, 1812-1818 (2005). (Pubitemid 46196642)
11. Liu K, Anderson GP, Bozinovski S: DNA vector augments inflammation in epithelial cells via EGFR-dependent regulation of TLR4 and TLR2. Am. J. Respir. Cell Mol. Biol. 39, 305-311 (2008).
12. Yu C, Irudayaraj J: Multiplex biosensor using gold nanorods. Anal. Chem. 79, 572-579 (2007). (Pubitemid 46106122)
13. Pissuwan D, Cortie CH, Valenzuela S, Cortie MB: Gold nanosphere-antibody conjugates for hypothermal therapeutic applications. Gold Bulletin 40, 121 (2007).
14. Geso M: Gold nanoparticles: a new X-ray contrast agent. Br. J. Radiol. 80, 64-65; Author reply 65 (2007). (Pubitemid 46470249)
15. Pernodet N, Fang X, Sun Y et al.: Adverse effects of citrate/gold nanoparticles on human dermal fibroblasts. Small 2, 766-773 (2006). (Pubitemid 43745149)
16. Patra HK, Banerjee S, Chaudhuri U, Lahiri P, Dasgupta AK: Cell selective response to gold nanoparticles. Nanomedicine 3, 111-119 (2007). (Pubitemid 46899618)
17. Lewinski N, Colvin V, Drezek R: Cytotoxicity of nanoparticles. Small 4, 26-49 (2008).
18. Uboldi C, Bonacchi D, Lorenzi G et al.: Gold nanoparticles induce cytotoxicity in the alveolar type-II cell lines A549 and NCIH441. Part. Fibre Toxicol. 6, 18 (2009).
19. Libutti SK, Paciotti GF, Byrnes AA et al.: Phase I and pharmacokinetic studies of CYT-6091, a novel PEGylated colloidal gold-rhTNF nanomedicine. Clin. Cancer Res. 16, 6139-6149 (2010).
20. McDevitt MR, Chattopadhyay D, Jaggi JS et al.: PET imaging of soluble yttrium-86- labeled carbon nanotubes in mice. PLoS One 2, E907 (2007).
21. Welsher K, Liu Z, Daranciang D, Dai H: Selective probing and imaging of cells with single walled carbon nanotubes as near-infrared fluorescent molecules. Nano Lett. 8, 586-590 (2008). (Pubitemid 351346022)
22. Lei J, Ju H: Nanotubes in biosensing. Wiley Interdiscip. Rev. Nanomed. Nanobiotechnol. 2, 496-509 (2010).
23. Nedosekin DA, Shashkov EV, Galanzha EI, Hennings L, Zharov VP: Photothermal multispectral image cytometry for quantitative histology of nanoparticles and micrometastasis in intact, stained and selectively burned tissues. Cytometry A. 77, 1049-1058 (2010).
24. de la Zerda A, Liu Z, Bodapati S et al.: Ultrahigh sensitivity carbon nanotube agents for photoacoustic molecular imaging in living mice. Nano Lett. 10, 2168-2172 (2010).
25. Liu S, Ng AK, Xu R et al.: Antibacterial action of dispersed single-walled carbon nanotubes on Escherichia coli and Bacillus subtilis investigated by atomic force microscopy. Nanoscale 2, 2744-2750 (2010).
26. Kim JW, Shashkov EV, Galanzha EI, Kotagiri N, Zharov VP: Photothermal antimicrobial nanotherapy and nanodiagnostics with self-assembling carbon nanotube clusters. Lasers Surg. Med. 39, 622-634 (2007). (Pubitemid 47505214)
27. Shao N, Lu S, Wickstrom E, Panchapakesan B: Integrated molecular targeting of IGF1R and HER2 surface receptors and destruction of breast cancer cells using single wall carbon nanotubes. Nanotechnology 18, 315101 (2007).
28. Huang N, Wang H, Zhao J, Lui H, Korbelik M, Zeng H: Single-wall carbon nanotubes assisted photothermal cancer therapy: animal study with a murine model of squamous cell carcinoma. Lasers Surg. Med. 42, 638-648 (2010).
29. Cai QY, Kim SH, Choi KS et al.: Colloidal gold nanoparticles as a blood-pool contrast agent for x-ray computed tomography in mice. Invest. Radiol. 42, 797-806 (2007). (Pubitemid 350126561)
30. Gao X: Multifunctional quantum dots for cellular and molecular imaging. Conf. Proc. IEEE Eng. Med. Biol. Soc. 2007, 524-525 (2007).
31. Gao J, Chen K, Miao Z et al.: Affibody-based nanoprobes for HER2-expressing cell and tumor imaging. Biomaterials 32(8), 2141-2148 (2011).
32. Gonda K, Watanabe TM, Ohuchi N, Higuchi H: In vivo nano-imaging of membrane dynamics in metastatic tumor cells using quantum dots. J. Biol. Chem. 285, 2750-2757 (2010).
33. Dubertret B, Skourides P, Norris DJ, Noireaux V, Brivanlou AH, Libchaber A: In vivo imaging of quantum dots encapsulated in phospholipid micelles. Science 298, 1759-1762 (2002). (Pubitemid 35404113)
34. Chang E, Thekkek N, Yu WW, Colvin VL, Drezek R: Evaluation of quantum dot cytotoxicity based on intracellular uptake. Small 2, 1412-1417 (2006). (Pubitemid 44786881)
35. Aillon KL, Xie Y, El-Gendy N, Berkland CJ, Forrest ML: Effects of nanomaterial physicochemical properties on in vivo toxicity. Adv. Drug Deliv. Rev. 61, 457-466 (2009).
36. KontermannRE: Immunoliposomes for cancer therapy. Curr. Opin. Mol. Ther. 8, 39-45 (2006). (Pubitemid 43230899)
37. Hatakeyama H, Akita H, Ishida E et al.: Tumor targeting of doxorubicin by anti-MT1-MMP antibody-modified PEG liposomes. Int. J. Pharm. 342, 194-200 (2007). (Pubitemid 47259319)
38. Nagae I, Koyanagi Y, Ito S, Tanabe Y, Unezaki S: Liposome drug delivery system for murine neuroblastoma. J. Pediatr. Surg. 33, 1521-1525 (1998). (Pubitemid 28480914)
39. Ranson MR, Cheeseman S, White S, Margison J: Caelyx (stealth liposomal doxorubicin) in the treatment of advanced breast cancer. Crit. Rev. Oncol. Hematol. 37, 115-120 (2001). (Pubitemid 32106910)
40. Andreopoulou E, Gaiotti D, Kim E et al.: Pegylated liposomal doxorubicin HCL (PLD; Caelyx/Doxil): experience with long-term maintenance in responding patients with recurrent epithelial ovarian cancer. Ann. Oncol. 18, 716-721 (2007). (Pubitemid 46523276)
41. Latagliata R, Breccia M, Fazi P et al.: Liposomal daunorubicin versus standard daunorubicin: long term follow-up of the GIMEMA GSI 103 AMLE randomized trial in patients older than 60 years with acute myelogenous leukaemia. Br. J. Haematol. 143, 681-689 (2008).
42. Camera A, Rinaldi CR, Palmieri S et al.: Sequential continuous infusion of fludarabine and cytarabine associated with liposomal daunorubicin (DaunoXome) (FLAD) in primary refractory or relapsed adult acute myeloid leukemia patients. Ann. Hematol. 88, 151-158 (2009).
43. Sparano JA, Makhson AN, Semiglazov VF et al.: Pegylated liposomal doxorubicin plus docetaxel significantly improves time to progression without additive cardiotoxicity compared with docetaxelmonotherapy in patients with advanced breast cancer previously treated with neoadjuvant-adjuvant anthracycline therapy: results from a randomized Phase III study. J. Clin. Oncol. 27, 4522-4529 (2009).
44. Duarte S, Faneca H, Pedroso de Lima MC: Non-covalent association of folate to lipoplexes: a promising strategy to improve gene delivery in the presence of serum. J. Control. Release DOI: 10.1016/j. jconrel.2010.10.032 (2010) (Epub ahead of print).
45. Kline CL, Shanmugavelandy SS, Kester M, Irby RB: Delivery of PAR-4 plasmid in vivo via nanoliposomes sensitizes colon tumor cells subcutaneously implanted into nude mice to 5-FU. Cancer Biol. Ther. 8, 1831-1837 (2009).
46. Chen Y, Bathula SR, Li J, Huang L: Multifunctional nanoparticles delivering small interfering RNA and doxorubicin overcome drug resistance in cancer. J. Biol. Chem. 285, 22639-22650 (2010).
47. Feng C, Wang T, Tang R et al.: Silencing of the MYCN gene by siRNA delivered by folate receptor-targeted liposomes in LA-N-5 cells. Pediatr. Surg. Int. 26, 1185-1191 (2010).
48. Pardridge WM: shRNA and siRNA delivery to the brain. Adv. Drug Deliv. Rev. 59, 141-152 (2007). (Pubitemid 46773051)
49. Geusens B, Lambert J, De Smedt SC, Buyens K, Sanders NN, Van Gele M: Ultradeformable cationic liposomes for delivery of small interfering RNA (siRNA) into human primary melanocytes. J. Control. Release 133(3), 214-220 (2009).
50. Mendonca LS, Moreira JN, de Lima MC, Simoes S: Co-encapsulation of anti-BCR-ABL siRNA and imatinibmesylate in transferrin receptor-targeted sterically stabilized liposomes for chronic myeloid leukemia treatment. Biotechnol. Bioeng. 107, 884-893 (2010).
51. Dufes C, Gaillard F, Uchegbu IF, Schatzlein AG, Olivier JC, Muller JM: Glucose-targeted niosomes deliver vasoactive intestinal peptide (VIP) to the brain. Int. J. Pharm. 285, 77-85 (2004). (Pubitemid 39361538)
52. Conacher M, Alexander J, Brewer JM: Niosomes as immunological adjuvants. In:Synthetic Surfactant Vesicles . Uchegbu I (Ed.). International Publishers Distrubtors, Singapore, 185-205 (2000).
53. Arora R, Jain CP: Advances in niosome as a drug carrier: a review. Asian J. Pharm. 1, 29-39 (2007).
54. Tomalia DA, Reyna LA, Svenson S: Dendrimers as multi-purpose nanodevices for oncology drug delivery and diagnostic imaging. Biochem. Soc. Trans. 35, 61-67 (2007).
55. Shukla R, Thomas TP, Peters JL et al.: HER2 specific tumor targeting with dendrimer conjugated anti-HER2 mAb. Bioconjug. Chem. 17, 1109-1115 (2006). (Pubitemid 44455317)
56. Ke W, Shao K, Huang R et al.: Gene delivery targeted to the brain using an angiopep-conjugated polyethyleneglycol-modified polyamidoaminedendrimer. Biomaterials 30, 6976-6985 (2009).
57. Santos JL, Oliveira H, Pandita D et al.: Functionalization of poly(amidoamine) dendrimers with hydrophobic chains for improved gene delivery in mesenchymal stem cells. J. Control. Release 144, 55-64 (2010).
58. Ofek P, Fischer W, Calderon M, Haag R, Satchi-Fainaro R: In vivo delivery of small interfering RNA to tumors and their vasculature by novel dendritic nanocarriers. FASEB J. 24(9), 3122-3134 (2010).
59. Dutta T, Burgess M, McMillan NA, Parekh HS: Dendrosome-based delivery of siRNA against E6 and E7 oncogenes in cervical cancer. Nanomedicine 6(3), 463-470 (2010).
60. Lim J, Chouai A, Lo ST, Liu W, Sun X, Simanek EE: Design, synthesis, characterization, and biological evaluation of triazinedendrimers bearing paclitaxel using ester and ester/disulfide linkages. Bioconjug. Chem. 20, 2154-2161 (2009).
61. Matsumoto S, Christie RJ, Nishiyama N et al.: Environment-responsive block copolymer micelles with a disulfide cross-linked core for enhanced siRNA delivery. Biomacromolecules 10, 119-127 (2009).
62. Takae S, Miyata K, Oba M et al.: PEG-detachable polyplex micelles based on disulfide-linked block catiomers as bioresponsivenonviral gene vectors. J. Am. Chem. Soc. 130, 6001-6009 (2008). (Pubitemid 351620847)
63. Luo Y, Wang A, Yuan J, Gao Q: Preparation, characterization and drug release behavior of polyion complex micelles. Int. J. Pharm. 374, 139-144 (2009).
64. Elbayoumi TA, Pabba S, Roby A, Torchilin VP: Antinucleosome antibody-modified liposomes and lipid-core micelles for tumor-targeted delivery of therapeutic and diagnostic agents. J. Liposome Res. 17, 1-14 (2007). (Pubitemid 46631140)
65. Yoo HS, Park TG: Folate receptor targeted biodegradable polymeric doxorubicin micelles. J. Control. Release 96, 273-283 (2004). (Pubitemid 38481509)
66. Koo OM, Rubinstein I, Onyuksel H: Camptothecin in sterically stabilized phospholipid micelles: a novel nanomedicine. Nanomedicine 1, 77-84 (2005). (Pubitemid 43963604)
67. Kawano K, Watanabe M, Yamamoto T et al.: Enhanced antitumor effect of camptothecin loaded in long-circulating polymeric micelles. J. Control. Release 112, 329-332 (2006).
68. Talelli M, Pispas S: Complexes of cationic block copolymer micelles with DNA: histone/DNA complex mimetics. Macromol. Biosci. 8, 960-967 (2008).
69. Yin L, Ding J, He C, Cui L, Tang C, Yin C: Drug permeability and mucoadhesion properties of thiolatedtrimethyl chitosan nanoparticles in oral insulin delivery. Biomaterials 30, 5691-5700 (2009).
70. Rekha MR, Sharma CP: Synthesis and evaluation of lauryl succinyl chitosan particles towards oral insulin delivery and absorption. J. Control. Release 135, 144-151 (2009).
71. George M, Abraham TE: Polyionic hydrocolloids for the intestinal delivery of protein drugs: alginate and chitosan - a review. J. Control. Release 114, 1-14 (2006). (Pubitemid 44131680)
72. Layre AM, Couvreur P, Chacun H et al.: Busulfan loading into poly(alkyl cyanoacrylate) nanoparticles: physico-chemistry and molecular modeling. J. Biomed. Mater. Res. B Appl. Biomater . 79, 254-262 (2006). (Pubitemid 44652049)
73. Kreuter J: Nanoparticles - a historical perspective. Int. J. Pharm. 331, 1-10 (2007).
74. Fay F, Quinn DJ, Gilmore BF, McCarron PA, Scott CJ: Gene delivery using dimethyldidodecylammonium bromide-coated PLGA nanoparticles. Biomaterials 31, 4214-4222 (2010).
75. Li S: Hydrolytic degradation characteristics of aliphatic polyesters derived from lactic and glycolic acids. J. Biomed. Mater. Res. 48, 342-353 (1999). (Pubitemid 29242707)
76. Owens DE 3rd, Peppas NA: Opsonization, biodistribution, and pharmacokinetics of polymeric nanoparticles. Int. J. Pharm. 307, 93-102 (2006). (Pubitemid 41773257)
77. Panagi Z, Beletsi A, Evangelatos G, Livaniou E, Ithakissios DS, Avgoustakis K: Effect of dose on the biodistribution and pharmacokinetics of PLGA and PLGA-mPEG nanoparticles. Int. J. Pharm. 221, 143-152 (2001). (Pubitemid 32524042)
78. Durand R, Paul M, Rivollet D, Houin R, Astier A, Deniau M: Activity of pentamidine-loaded methacrylate nanoparticles against Leishmaniainfantum in a mouse model. Int. J. Parasitol. 27, 1361-1367 (1997). (Pubitemid 27502238)
79. Ruehm SG, Corot C, Vogt P, Kolb S, Debatin JF: Magnetic resonance imaging of atherosclerotic plaque with ultrasmallsuperparamagnetic particles of iron oxide in hyperlipidemic rabbits. Circulation 103, 415-422 (2001). (Pubitemid 32105982)
80. Kim JY, Kim JK, Park JS, Byun Y, Kim CK: The use of PEGylated liposomes to prolong circulation lifetimes of tissue plasminogen activator. Biomaterials 30, 5751-5756 (2009).
81. Hu Y, Xie J, Tong YW, Wang CH: Effect of PEG conformation and particle size on the cellular uptake efficiency of nanoparticles with the HepG2 cells. J. Control. Release 118, 7-17 (2007). (Pubitemid 46283099)
82. Alexis F, Pridgen E, Molnar LK, Farokhzad OC: Factors affecting the clearance and biodistribution of polymeric nanoparticles. Mol. Pharm. 5, 505-515 (2008).
83. Moffatt S, Cristiano RJ: Uptake characteristics of NGR-coupled stealth PEI/pDNA nanoparticles loaded with PLGA-PEG-PLGA tri-block copolymer for targeted delivery to human monocyte-derived dendritic cells. Int. J. Pharm. 321, 143-154 (2006). (Pubitemid 44247413)
84. Garinot M, Fievez V, Pourcelle V et al.: PEGylated PLGA-based nanoparticles targeting M cells for oral vaccination. J. Control. Release 120, 195-204 (2007). (Pubitemid 47061488)
85. Dhar S, Gu FX, Langer R, Farokhzad OC, Lippard SJ: Targeted delivery of cisplatin to prostate cancer cells by aptamer functionalized Pt(IV) prodrug-PLGA-PEG nanoparticles. Proc. Natl Acad. Sci. USA 105, 17356-17361 (2008).
86. Garg A, Tisdale AW, Haidari E, Kokkoli E: Targeting colon cancer cells using PEGylated liposomes modified with a fibronectin-mimetic peptide. Int. J. Pharm. 366, 201-210 (2009).
87. Kim SH, Jeong JH, Chun KW, Park TG: Target-specific cellular uptake of PLGA nanoparticles coated with poly(l-lysine)- poly(ethylene glycol)-folate conjugate. Langmuir 21, 8852-8857 (2005). (Pubitemid 41396646)
88. Brandhonneur N, Chevanne F, Vie V et al.: Specific and non-specific phagocytosis of ligand-grafted PLGA microspheres by macrophages. Eur. J. Pharm. Sci. 36(4-5), 474-485 (2009).
89. Lu W, Huang Q, Ku G et al.: Photoacoustic imaging of living mouse brain vasculature using hollow gold nanospheres. Biomaterials 31, 2617-2626 (2010).
90. Kim JH, Kim YS, Park K et al.: Antitumor efficacy of cisplatin-loaded glycol chitosan nanoparticles in tumor-bearing mice. J. Control. Release 127, 41-49 (2008).
91. Chytil P, Etrych T, Konak C et al.: New HPMA copolymer-based drug carriers with covalently bound hydrophobic substituents for solid tumour targeting. J. Control. Release 127, 121-130 (2008).
92. Elbayoumi TA, Torchilin VP: Tumor-specific antibody-mediated targeted delivery of Doxil reduces the manifestation of auricular erythema side effect in mice. Int. J. Pharm. 357, 272-279 (2008).
93. Gupta PN, Khatri K, Goyal AK, Mishra N, Vyas SP: M-cell targeted biodegradable PLGA nanoparticles for oral immunization against hepatitis B. J. Drug Target 15, 701-713 (2007). (Pubitemid 350201323)
94. Zhang Z, Huey Lee S, Feng SS: Folate-decorated poly(lactide-co-glycolide) - vitamin E TPGS nanoparticles for targeted drug delivery. Biomaterials 28, 1889-1899 (2007). (Pubitemid 46137995)
95. Eliaz RE, Szoka FC Jr: Liposome-encapsulated doxorubicin targeted to CD44: a strategy to kill CD44-overexpressing tumor cells. Cancer Res. 61, 2592-2601 (2001). (Pubitemid 32685844)
96. Farokhzad OC, Cheng J, Teply BA et al.: Targeted nanoparticle- aptamerbioconjugates for cancer chemotherapy in vivo. Proc. Natl Acad. Sci. USA 103, 6315-6320 (2006).
97. Lu J, Shi M, Shoichet MS: Click chemistry functionalized polymeric nanoparticles target corneal epithelial cells through RGD-cell surface receptors. Bioconjug. Chem. 20, 87-94 (2009).
98. Singh SR, Grossniklaus HE, Kang SJ, Edelhauser HF, Ambati BK, Kompella UB: Intravenous transferrin, RGD peptide and dual-targeted nanoparticles enhance anti-VEGF intraceptor gene delivery to laser-induced CNV. Gene Ther. 16, 645-659 (2009).
99. Hu Z, Luo F, Pan Y et al.: Arg-Gly-Asp (RGD) peptide conjugated poly(lactic acid)-poly(ethylene oxide) micelle for targeted drug delivery. J. Biomed. Mater. Res. A 85, 797-807 (2008). (Pubitemid 351632893)
100. Gao X, Chen J, Tao W et al.: UEA I-bearing nanoparticles for brain delivery following intranasal administration. Int. J. Pharm. 340(1-2), 207-215 (2007). (Pubitemid 47043363)
101. Gupta PN, Mahor S, Rawat A, Khatri K, Goyal A, Vyas SP: Lectin anchored stabilized biodegradable nanoparticles for oral immunization 1. Development and in vitro evaluation. Int. J. Pharm. 318, 163-173 (2006). (Pubitemid 43963301)
102. Wang J, Tian S, Petros RA, Napier ME, Desimone JM: The complex role of multivalency in nanoparticles targeting the transferrin receptor for cancer therapies. J. Am. Chem. Soc. 132, 11306-11313 (2010).
103. Ulbrich K, Hekmatara T, Herbert E, Kreuter J: Transferrin- and transferrin-receptor-antibody-modified nanoparticles enable drug delivery across the blood-brain barrier (BBB). Eur. J. Pharm. Biopharm. 71, 251-256 (2009).
104. Cirstoiu-Hapca A, Buchegger F, Lange N, Bossy L, Gurny R, Delie F: Benefit of anti-HER2-coated paclitaxel-loaded immuno-nanoparticles in the treatment of disseminated ovarian cancer: therapeutic efficacy and biodistribution in mice. J. Control. Release 144, 324-331 (2010).
105. Scott CJ, Marouf WM, Quinn DJ et al.: Immunocolloidal targeting of the endocytotic siglec-7 receptor using peripheral attachment of siglec-7 antibodies to poly(lactide-co-glycolide) nanoparticles. Pharm. Res. 25, 135-146 (2008).
106. Gleysteen JP, Newman JR, Chhieng D, Frost A, Zinn KR, Rosenthal EL: Fluorescent labeled anti-EGFR antibody for identification of regional and distant metastasis in a preclinical xenograft model. Head Neck 30(6), 782-789 (2008). (Pubitemid 351913856)
107. Lode HN, Xiang R, Becker JC, Gillies SD, Reisfeld RA: Immunocytokines: a promising approach to cancer immunotherapy. Pharmacol. Ther. 80, 277-292 (1998). (Pubitemid 28537824)
108. Kerr DE, Vrudhula VM, Svensson HP, Siemers NO, Senter PD: Comparison of recombinant and synthetically formed monoclonal antibody-b-lactamase conjugates for anticancer prodrug activation. Bioconjug. Chem. 10, 1084-1089 (1999).
109. Wolfe LA, Mullin RJ, Laethem R et al.: Antibody-directed enzyme prodrug therapy with the T268G mutant of human carboxypeptidase A1: in vitro and in vivo studies with prodrugs of methotrexate and the thymidylate synthase inhibitors GW1031 and GW1843. Bioconjug. Chem. 10, 38-48 (1999). (Pubitemid 29062516)
110. Kawakami K, Nakajima O, Morishita R, Nagai R: Targeted anticancer immunotoxins and cytotoxic agents with direct killing moieties. ScientificWorldJournal 6, 781-790 (2006).
111. Hamann PR, Hinman LM, Hollander I et al.: Gemtuzumabozogamicin, a potent and selective anti-CD33 antibody-calicheamicin conjugate for treatment of acute myeloid leukemia. Bioconjug. Chem. 13, 47-58 (2002). (Pubitemid 34119634)
112. Henry MD, Wen S, Silva MD, Chandra S, Milton M, Worland PJ: A prostate-specific membrane antigen-targeted monoclonal antibody-chemotherapeutic conjugate designed for the treatment of prostate cancer. Cancer Res. 64, 7995-8001 (2004). (Pubitemid 39446934)
113. Sorokin P: Mylotarg approved for patients with CD33+ acute myeloid leukemia. Clin. J. Oncol. Nurs. 4, 279-280 (2000).
114. Jacobs SA: Yttrium ibritumomabtiuxetan in the treatment of non-Hodgkin's lymphoma: current status and future prospects. Biologics 1, 215-227 (2007).
115. Vitolo U, Barosi G, Fanti S et al.: Consensus conference on the use of 90-yttrium-ibritumomab tiuxetantherapy in clinical practice. A project of the Italian Society of Hematology. Am. J. Hematol. 85, 147-155 (2010).
116. Park JW, Kirpotin DB, Hong K et al.: Tumor targeting using anti-Her2 immunoliposomes. J. Control. Release 74, 95-113 (2001). (Pubitemid 32727613)
117. Tuffin G, Waelti E, Huwyler J, Hammer C, Marti HP: Immunoliposome targeting to mesangial cells: a promising strategy for specific drug delivery to the kidney. J. Am. Soc. Nephrol. 16, 3295-3305 (2005). (Pubitemid 46179334)
118. McCarron PA, Marouf WM, Donnelly RF, Scott C: Enhanced surface attachment of protein-type targeting ligands to poly(lactide-co-glycolide) nanoparticles using variable expression of polymeric acid functionality. J. Biomed. Mater. Res. A 87(4), 873-884 (2008).
119. Herbst RS, Fukuoka M, Baselga J: Gefitinib - a novel targeted approach to treating cancer. Nat. Rev. Cancer 4, 956-965 (2004). (Pubitemid 39626219)
120. Acharya S, Dilnawaz F, Sahoo SK: Targeted epidermal growth factor receptor nanoparticle bioconjugates for breast cancer therapy. Biomaterials 30, 5737-5750 (2009).
121. Hanawa M, Suzuki S, Dobashi Y et al.: EGFR protein overexpression and gene amplification in squamous cell carcinomas of the esophagus. Int. J. Cancer 118, 1173-1180 (2006). (Pubitemid 43185604)
122. Bhargava R, Gerald WL, Li AR et al.: EGFR gene amplification in breast cancer: correlation with epidermal growth factor receptor mRNA and protein expression and HER-2 status and absence of EGFR-activating mutations. Mod. Pathol. 18, 1027-1033 (2005). (Pubitemid 41224492)
123. Kocbek P, Obermajer N, Cegnar M, Kos J, Kristl J: Targeting cancer cells using PLGA nanoparticles surface modified with monoclonal antibody. J. Control. Release 120, 18-26 (2007). (Pubitemid 46874614)
124. Tejani MA, Cohen RB, Mehra R: The contribution of cetuximab in the treatment of recurrent and/or metastatic head and neck cancer. Biologics 4, 173-185 (2010).
125. Fakih M, Wong R: Efficacy of the monoclonal antibody EGFR inhibitors for the treatment of metastatic colorectal cancer. Curr. Oncol. 17(Suppl. 1), S3-S17 (2010).
126. Talavera A, Friemann R, Gomez-Puerta S et al.: Nimotuzumab, an antitumor antibody that targets the epidermal growth factor receptor, blocks ligand binding while permitting the active receptor conformation. Cancer Res. 69, 5851-5859 (2009).
127. Gupta B, Torchilin VP: Monoclonal antibody 2C5-modified doxorubicin-loaded liposomes with significantly enhanced therapeutic activity against intracranial human brain U-87 MG tumorxenografts in nude mice. Cancer Immunol. Immunother. 56, 1215-1223 (2007). (Pubitemid 46763936)
128. Mamot C, Ritschard R, Kung W, Park JW, Herrmann R, Rochlitz CF: EGFR-targeted immunoliposomes derived from the monoclonal antibody EMD72000 mediate specific and efficient drug delivery to a variety of colorectal cancer cells. J. Drug Target 14, 215-223 (2006).
129. Wu G, Yang W, Barth RF et al.: Molecular targeting and treatment of an epidermal growth factor receptor-positive glioma using boronatedcetuximab. Clin. Cancer Res. 13, 1260-1268 (2007). (Pubitemid 46437053)
130. Mallidi S, Larson T, Aaron J, Sokolov K, Emelianov S: Molecular specific optoacoustic imaging with plasmonic nanoparticles. Opt. Express 15, 6583-6588 (2007). (Pubitemid 46827656)
131. El-Sayed IH, Huang X, El-Sayed MA: Selective laser photo-thermal therapy of epithelial carcinoma using anti-EGFR antibody conjugated gold nanoparticles. Cancer Lett. 239, 129-135 (2006). (Pubitemid 43946581)
132. Glazer ES, Massey KL, Zhu C, Curley SA: Pancreatic carcinoma cells are susceptible to noninvasive radio frequency fields after treatment with targeted gold nanoparticles. Surgery 148, 319-324 (2010).
133. Peus D, Hamacher L, Pittelkow MR: EGF-receptor tyrosine kinase inhibition induces keratinocyte growth arrest and terminal differentiation. J. Invest. Dermatol. 109, 751-756 (1997). (Pubitemid 28053524)
134. Voldborg BR, Damstrup L, Spang-Thomsen M, Poulsen HS: Epidermal growth factor receptor (EGFR) and EGFR mutations, function and possible role in clinical trials. Ann. Oncol. 8, 1197-1206 (1997). (Pubitemid 28164074)
135. Sainsbury JR, Farndon JR, Needham GK, Malcolm AJ, Harris AL: Epidermal-growth-factor receptor status as predictor of early recurrence of and death from breast cancer. Lancet 1, 1398-1402 (1987). (Pubitemid 17078859)
136. Minner S, Jessen B, Stiedenroth L et al.: Low level HER2 overexpression is associated with rapid tumor cell proliferation and poor prognosis in prostate cancer. Clin. Cancer Res. 16, 1553-1560 (2010).
137. Farzadnia M, Meibodi NT, Shandiz FH et al.: Evaluation of HER2/neuoncoprotein in serum and tissue samples of women with breast cancer: correlation with clinicopathological parameters. Breast 19, 489-492 (2010).
138. Goldhirsch A, Ingle JN, Gelber RD et al.: Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the primary therapy of early breast cancer 2009. Ann. Oncol. 20, 1319-1329 (2009).
139. Hall PS, Cameron DA: Current perspective - trastuzumab. Eur. J. Cancer 45, 12-18 (2009).
140. Nielsen DL, Andersson M, Kamby C: HER2-targeted therapy in breast cancer. Monoclonal antibodies and tyrosine kinase inhibitors. Cancer Treat. Rev. 35, 121-136 (2009).
141. Lievens Y: Cost-effectiveness of adjuvant trastuzumab in early breast cancer: is less better? Belg. J. Med. Oncol. 4, 33-37 (2010).
142. Banerjee S, Smith IE: Management of small HER2-positive breast cancers. Lancet Oncol. 11, 1193-1199 (2010).
143. Cirstoiu-Hapca A, Bossy-Nobs L, Buchegger F, Gurny R, Delie F: Differential tumor cell targeting of anti-HER2 (Herceptin) and anti-CD20 (Mabthera) coupled nanoparticles. Int. J. Pharm. 331, 190-196 (2007). (Pubitemid 46216679)
144. Jiang W, Kim BY, Rutka JT, Chan WC: Nanoparticle-mediated cellular response is size-dependent. Nat. Nanotechnol. 3, 145-150 (2008). (Pubitemid 351355131)
145. Chiu GN, Edwards LA, Kapanen AI et al.: Modulation of cancer cell survival pathways using multivalent liposomal therapeutic antibody constructs. Mol. Cancer Ther. 6, 844-855 (2007). (Pubitemid 46554554)
146. Huang YF, Liu H, Xiong X, Chen Y, Tan W: Nanoparticle-mediated IgE-receptor aggregation and signaling in RBL mast cells. J. Am. Chem. Soc. 131, 17328-17334 (2009).
147. Wang J, Tian S, Petros RA, Napier ME, Desimone JM: The complex role of multivalency in nanoparticles targeting the transferrin receptor for cancer therapies. J. Am. Chem. Soc. 132, 11306-11313 (2010).
148. McCarron PA, Marouf WM, Quinn DJ et al.: Antibody targeting of camptothecin-loaded PLGA nanoparticles to tumor cells. Bioconjug. Chem. 19, 1561-1569 (2008).
149. Ferrara N, Gerber HP, LeCouter J: The biology of VEGF and its receptors. Nat. Med. 9, 669-676 (2003). (Pubitemid 36749215)
150. Hendrix MJ, Seftor EA, Kirschmann DA, Quaranta V, Seftor RE: Remodeling of the microenvironment by aggressive melanoma tumor cells. Ann. NY Acad. Sci. 995, 151-161 (2003). (Pubitemid 36706622)
151. Soman C, Giorgio T: Sensitive and multiplexed detection of proteomic antigens via quantum dot aggregation. Nanomedicine 5, 402-409 (2009).
152. Towner RA, Smith N, Asano Y et al.: Molecular magnetic resonance imaging approaches used to aid in the understanding of angiogenesis in vivo: implications for tissue engineering. Tissue Eng. Part A 16, 357-364 (2010).
153. Mukherjee P, Bhattacharya R, Bone N et al.: Potential therapeutic application of gold nanoparticles in B-chronic lymphocytic leukemia (BCLL): enhancing apoptosis. J. Nanobiotechnol. 5, 4 (2007).
154. Chen J, Wu H, Han D, Xie C: Using anti-VEGF McAb and magnetic nanoparticles as double-targeting vector for the radioimmunotherapy of liver cancer. Cancer Lett. 231, 169-175 (2006). (Pubitemid 43038727)
155. Mhawech-Fauceglia P, Smiraglia DJ, Bshara W et al.: Prostate-specific membrane antigen expression is a potential prognostic marker in endometrial adenocarcinoma. Cancer Epidemiol. Biomarkers Prev. 17, 571-577 (2008). (Pubitemid 351469206)
156. Minner S, Wittmer C, Graefen M et al.: High level PSMA expression is associated with early PSA recurrence in surgically treated prostate cancer. Prostate 71(3), 281-288 (2011).
157. Tjoa BA, Simmons SJ, Bowes VA et al.: Evaluation of Phase I/II clinical trials in prostate cancer with dendritic cells and PSMA peptides. Prostate 36, 39-44 (1998). (Pubitemid 28285638)
158. Naylor PH, Hernandez KE, Nixon AE et al.: IRX-2 increases the T cell-specific immune response to protein/peptide vaccines. Vaccine 28(43), 7054-7062 (2010).
159. Henry MD, Wen S, Silva MD, Chandra S, Milton M, Worland PJ: A prostate-specific membrane antigen-targeted monoclonal antibody-chemotherapeutic conjugate designed for the treatment of prostate cancer. Cancer Res. 64, 7995-8001 (2004). (Pubitemid 39446934)
160. Ma D, Hopf CE, Malewicz AD et al.: Potent antitumor activity of an auristatin-conjugated, fully human monoclonal antibody to prostate-specific membrane antigen. Clin. Cancer Res. 12, 2591-2596 (2006).
161. Kuroda K, Liu H, Kim S, Guo M, Navarro V, Bander NH: Saporin toxin-conjugated monoclonal antibody targeting prostate-specific membrane antigen has potent anticancer activity. Prostate 70, 1286-1294 (2010).
162. Milowsky MI, Nanus DM, Kostakoglu L, Vallabhajosula S, Goldsmith SJ, Bander NH: Phase I trial of yttrium-90-labeled anti-prostate-specific membrane antigen monoclonal antibody J591 for androgen-independent prostate cancer. J. Clin. Oncol. 22, 2522-2531 (2004). (Pubitemid 41103739)
163. Smith-Jones PM, Vallabhajosula S, Navarro V, Bastidas D, Goldsmith SJ, Bander NH: Radiolabeled monoclonal antibodies specific to the extracellular domain of prostate-specific membrane antigen: preclinical studies in nude mice bearing LNCaP human prostate tumor. J. Nucl. Med. 44, 610-617 (2003). (Pubitemid 40003748)
164. Thomas TP, Patri AK, Myc A et al.: In vitro targeting of synthesized antibody-conjugated dendrimer nanoparticles. Biomacromolecules 5, 2269-2274 (2004). (Pubitemid 39585279)
165. Gao X, Cui Y, Levenson RM, Chung LW, Nie S: In vivo cancer targeting and imaging with semiconductor quantum dots. Nat. Biotechnol. 22, 969-976 (2004). (Pubitemid 39014473)
166. Cheng Y, Zak O, Aisen P, Harrison SC, Walz T: Structure of the human transferrin receptor-transferrin complex. Cell 116, 565-576 (2004). (Pubitemid 38264433)
167. Gatter KC, Brown G, Trowbridge IS, Woolston RE, Mason DY: Transferrin receptors in human tissues: their distribution and possible clinical relevance. J. Clin. Pathol. 36, 539-545 (1983). (Pubitemid 13089724)
168. Davis ME, Zuckerman JE, Choi CH et al.: Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles. Nature 464, 1067-1070 (2010).
169. Yoon DJ, Kwan BH, Chao FC et al.: Intratumoral therapy of glioblastomamultiforme using genetically engineered transferrin for drug delivery. Cancer Res. 70, 4520-4527 (2010).
170. Koppu S, Oh YJ, Edrada-Ebel R et al.: Tumor regression after systemic administration of a novel tumor-targeted gene delivery system carrying a therapeutic plasmid DNA. J. Control. Release 143, 215-221 (2010).
171. Tacken PJ, de Vries IJ, Torensma R, Figdor CG: Dendritic-cell immunotherapy: from ex vivo loading to in vivo targeting. Nat. Rev. Immunol. 7, 790-802 (2007). (Pubitemid 47480309)
172. Kwon YJ, James E, Shastri N, Frechet JM: In vivo targeting of dendritic cells for activation of cellular immunity using vaccine carriers based on pH-responsive microparticles. Proc. Natl Acad. Sci. USA 102, 18264-18268 (2005). (Pubitemid 43011215)
173. Cruz LJ, Tacken PJ, Fokkink R et al.: Targeted PLGA nano- but not microparticles specifically deliver antigen to human dendritic cells via DC-SIGN in vitro. J. Control. Release 144, 118-126 (2010).
174. Skotland T, Iversen TG, Sandvig K: New metal-based nanoparticles for intravenous use: requirements for clinical success with focus on medical imaging. Nanomedicine 6,730-737 (2010).
175. Cannon GJ, Swanson JA: The macrophage capacity for phagocytosis. J. Cell. Sci. 101(Pt 4), 907-913 (1992).
176. Limburg PC, Bijl M: Autoantibodies to opsonins of apoptotic cells in systemic lupus erythematosus. Ann. Rheum. Dis. 64, 1669-1670 (2005). (Pubitemid 41667137)
177. Nobes C, Marsh M: Dendritic cells: new roles for Cdc42 and Rac in antigen uptake? Curr. Biol. 10, R739-R741 (2000).
178. Kolpak AL, Jiang J, Guo D et al.: Negative guidance factor-induced macropinocytosis in the growth cone plays a critical role in repulsive axon turning. J. Neurosci. 29, 10488-10498 (2009).
179. Dauty E, Remy JS, Zuber G, Behr JP: Intracellular delivery of nanometric DNA particles via the folate receptor. Bioconjug. Chem. 13, 831-839 (2002). (Pubitemid 34801126)
180. Pelkmans L, Helenius A: Endocytosis via caveolae. Traffic 3, 311-320 (2002). (Pubitemid 34461041)
181. Conner SD, Schmid SL: Regulated portals of entry into the cell. Nature 422, 37-44 (2003). (Pubitemid 36323287)
182. Wolfe BL, Trejo J: Clathrin-dependent mechanisms of G protein-coupled receptor endocytosis. Traffic 8, 462-470 (2007). (Pubitemid 46638559)
183. Zwang Y, Yarden Y: Systems biology of growth factor-induced receptor endocytosis. Traffic 10, 349-363 (2009).
184. Sun B, Ranganathan B, Feng SS: Multifunctional poly(d,l-lactide-co- glycolide)/montmorillonite (PLGA/MMT) nanoparticles decorated by trastuzumab for targeted chemotherapy of breast cancer. Biomaterials 29, 475-486 (2008). (Pubitemid 350110345)
185. Bernardi RJ, Lowery AR, Thompson PA, Blaney SM, West JL: Immunonanoshells for targeted photothermal ablation in medulloblastoma and glioma: an in vitro evaluation using human cell lines. J. Neurooncol. 86, 165-172 (2008). (Pubitemid 350263413)